SCHEMBL21753344

SCHEMBL21753344

Cc1cnccc1-c1ccc(CCl)cc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 3/20 0.38
CCNC P24863 2/20 0.37
CDK8 P49336 2/20 0.37
CYP1A2 P05177 2/20 0.37
METAP2 P50579 1/20 0.37
PDE2A O00408 2/20 0.35
PDE10A Q9Y233 2/20 0.35
CYP46A1 Q9Y6A2 1/20 0.35
GRM4 Q14833 1/20 0.35
GPBAR1 Q8TDU6 2/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
EIF4E P06730 1/20 0.34
CYP19A1 P11511 1/20 0.34
PRKCH P24723 1/20 0.34
PRKCE Q02156 1/20 0.34
PRKCQ Q04759 1/20 0.34
PRKCD Q05655 1/20 0.34
PPARG P37231 1/20 0.34
RORC P51449 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5492827 0.83 ESR1 (0.38)
SCHEMBL21753294 0.83 CCNC (0.40) CYP17A1CCNCCDK8CYP1A2METAP2
SCHEMBL21770335 0.79 SLC2A1 (0.48) CYP17A1CYP1A2PDE3BPDE3ACYP19A1
SCHEMBL3423341 0.77 CCNC (0.50) CCNCCDK8CYP1A2METAP2PDE2A
SCHEMBL28234716 0.76 MAP4K4 (0.36) CYP1A2PPARGRORC
SCHEMBL21753348 0.73 TDO2 (0.38) CYP1A2PDE2APDE10APDE3BPDE3A
SCHEMBL15063371 0.72 RARB (0.39) PPARGRORCS1PR1S1PR3
SCHEMBL21753328 0.70 KDM4E (0.44) CYP1A2METAP2
SCHEMBL21753283 0.70 MMP13 (0.41) CCNCCDK8GRM4CYP19A1HAVCR2
SCHEMBL21753295 0.69 ALDH1A3 (0.42) CYP17A1CCNCCDK8CYP1A2METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 US disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 WO disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP CYP17A1 880/4885CCNC 2351/4885CDK8 2570/4885
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS PREP, GAA, DNPEP CYP17A1 772/4885CCNC 2520/4885CDK8 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.